GLP-1RAs Explored for Weight, Metabolism, and Fat Distribution in Type 2 Diabetes

Type 2 diabetes mellitus (T2DM) and obesity are global health crises, often co-occurring and leading to severe complications like non-alcoholic fatty liver disease and cardiovascular issues. GLP-1 receptor agonists (GLP-1RAs) are a class of drugs known for their efficacy in improving glycemic control and promoting weight loss. However, a comprehensive analysis of their specific effects on glucose and lipid metabolism and detailed fat distribution in overweight/obese patients with T2DM is still needed to fully understand their therapeutic potential. This study aims to precisely analyze how GLP-1RAs impact these metabolic parameters and body fat distribution.

As this is an ongoing study, specific results are not yet available. However, based on the known efficacy of GLP-1RAs from extensive prior research, the investigators anticipate significant improvements across several metabolic markers. They expect to observe a substantial body weight reduction, typically ranging from 5-15% with Liraglutide and 10-20% with Semaglutide, in the treated overweight/obese patients with type 2 diabetes. > The primary anticipated finding is a significant improvement in glycemic control, evidenced by a reduction in HbA1c levels, potentially by 1.0-2.0% from baseline. Furthermore, improvements in lipid profiles (e.g., reduced triglycerides by 15-25% and LDL cholesterol by 5-10%) and a favorable shift in fat distribution (specifically, decreased abdominal and visceral fat) are expected. These comprehensive metabolic benefits are crucial for mitigating complications associated with type 2 diabetes and obesity.